Open AccessPotential biomarkers and resistance mechanisms of atezolizumab in a patient with lung squamous cell carcinoma
Author(s) -
Kangqi Ren,
Quanzhou Peng,
Guanggui Ding,
Yefeng Yu,
Tonghai Huang,
Longlong Gong,
Tao Yu,
Lin Yang
Publication year - 2022
Publication title -
immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.127
H-Index - 48
eISSN - 1750-7448
pISSN - 1750-743X
DOI - 10.2217/imt-2020-0325
Subject(s) - atezolizumab , pten , medicine , lung cancer , cancer research , immune checkpoint , immunotherapy , immune system , oncology , immunology , nivolumab , biology , pi3k/akt/mtor pathway , signal transduction , biochemistry
Background: At present, only a small fraction of patients with cancer benefit from treatment with immune checkpoint inhibitors, the reasons for which are not fully understood. Monitoring molecular and immunologic changes during treatment with immune checkpoint inhibitors would help to identify potential biomarkers and mechanisms associated with resistance and guide subsequent treatment. Methods: The authors report on a patient previously treated for lung squamous cell carcinoma who received atezolizumab-based therapy for 24 months. Results & Conclusion: Analysis of samples before and after atezolizumab treatment suggested that genetic mutations in EGFR exon 20 insertion, phosphatase and PTEN and NOTCH1 as well as changes in tumor immune microenvironment may be associated with acquired resistance to immune checkpoint inhibitor therapy.